Exosomal transfer of miR-126 promotes the anti-tumour response in malignant mesothelioma: Role of miR-126 in cancer-stroma communication.
Calcium-Binding Proteins
/ metabolism
Carcinogenesis
/ metabolism
Cell Communication
/ physiology
Cells, Cultured
EGF Family of Proteins
/ metabolism
Exosomes
/ metabolism
Fibroblasts
/ metabolism
Humans
Lung Neoplasms
/ metabolism
Mesothelioma
/ metabolism
Mesothelioma, Malignant
MicroRNAs
/ metabolism
Signal Transduction
/ physiology
Vascular Endothelial Growth Factor A
/ metabolism
Cancer stroma
Exosomes
Malignant mesothelioma
miR-126
miRNA-based therapy
Journal
Cancer letters
ISSN: 1872-7980
Titre abrégé: Cancer Lett
Pays: Ireland
ID NLM: 7600053
Informations de publication
Date de publication:
28 Oct 2019
28 Oct 2019
Historique:
received:
16
05
2019
revised:
26
07
2019
accepted:
05
08
2019
pubmed:
11
8
2019
medline:
22
5
2020
entrez:
11
8
2019
Statut:
ppublish
Résumé
MiR-126 has been shown to suppress malignant mesothelioma (MM) by targeting cancer-related genes without inducing toxicity or histopathological changes. Exosomes provide the opportunity to deliver therapeutic cargo to cancer stroma. Here, a tumour stromal model composed of endothelial cells (HUVECs), fibroblasts (IMR-90 cells), non-malignant mesothelial cells (Met-5A cells) and MM cells (H28 and MM-B1 cells) was used. The cells were treated with exosomes from HUVECs carrying endogenous (exo-HUVEC) and enriched miR-126 (exo-HUVEC
Identifiants
pubmed: 31400405
pii: S0304-3835(19)30424-0
doi: 10.1016/j.canlet.2019.08.001
pii:
doi:
Substances chimiques
Calcium-Binding Proteins
0
EGF Family of Proteins
0
EGFL7 protein, human
0
MIRN126 microRNA, human
0
MicroRNAs
0
Vascular Endothelial Growth Factor A
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
27-36Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.